Trial Profile
A 12-month, Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen (TER) of Aflibercept (EYLEA) 2mg /0.05 ml as a Second Line Treatment for Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms The TADI
- 12 Sep 2018 Status changed to completed.
- 22 Dec 2015 New trial record